Enovis Corporation $ENOV Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its stake in Enovis Corporation (NYSE:ENOV) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 757,673 shares of the company’s stock after buying an additional 78,497 shares during the period. Allspring Global Investments Holdings LLC owned approximately 1.32% of Enovis worth $20,086,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Impax Asset Management Group plc raised its holdings in Enovis by 47.5% during the third quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after purchasing an additional 100,000 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in Enovis during the third quarter worth $4,045,000. Vanguard Group Inc. grew its holdings in Enovis by 2.0% in the third quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after purchasing an additional 125,460 shares during the last quarter. Osaic Holdings Inc. increased its position in shares of Enovis by 56.0% in the second quarter. Osaic Holdings Inc. now owns 139,727 shares of the company’s stock valued at $4,382,000 after buying an additional 50,156 shares in the last quarter. Finally, Invenomic Capital Management LP increased its position in shares of Enovis by 22.7% in the third quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock valued at $21,622,000 after buying an additional 131,705 shares in the last quarter. 98.45% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Enovis news, insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction on Friday, February 27th. The shares were bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider directly owned 43,640 shares in the company, valued at $1,112,820. This trade represents a 2.35% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last three months, insiders acquired 5,000 shares of company stock valued at $121,983. Insiders own 2.70% of the company’s stock.

Wall Street Analyst Weigh In

ENOV has been the topic of several recent research reports. Wells Fargo & Company upgraded shares of Enovis to a “strong-buy” rating in a research report on Wednesday, March 18th. UBS Group restated a “buy” rating and set a $50.00 target price on shares of Enovis in a report on Monday, January 5th. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Monday, March 30th. Canaccord Genuity Group reduced their price target on shares of Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Finally, Needham & Company LLC increased their price target on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Enovis presently has an average rating of “Buy” and a consensus price target of $47.43.

Enovis Trading Up 0.4%

Shares of ENOV stock opened at $22.73 on Friday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -1.10 and a beta of 1.47. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. The firm has a 50-day moving average price of $22.94 and a 200 day moving average price of $26.88. Enovis Corporation has a twelve month low of $21.00 and a twelve month high of $37.85.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The company had revenue of $575.76 million for the quarter, compared to analysts’ expectations of $584.30 million. During the same period last year, the company earned $0.98 EPS. The firm’s revenue for the quarter was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts forecast that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Enovis Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.